49 completed, 4 terminated, 4 unknown, 2 recruiting. 61 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 61 | Completed 49, Terminated 4, Unknown 4, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Telmisartan: new trials by email Literature Review of Telmisartan trials Research Report on Telmisartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD) | Phase 3 | Recruiting | University College, London | 1200 | 2025-09-12 | 2025-10-03 |
| A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension THP-00101, THP-00102, THP-00103 - Type 2 Diabetes, Hypertension | Phase 3 | Active not recruiting | THPharm Corp. | 222 | 2025-04-10 | 2026-11-09 |
| Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension Egito, Empagliflozin + telmisartan - Hypertension Associated, Type II Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2023-08-01 | 2023-09-08 | |
| Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 1385 | 2021-07-09 | 2025-06-03 |
| Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 755 | 2021-06-14 | 2025-06-03 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 294 | 2020-11-27 | 2024-12-27 |
| Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Losartan, Valsartan, Azilsartan - Covid19, SARS-CoV Infection | Phase 3 | Terminated | University of British Columbia | 341 | 2020-10-09 | 2023-02-16 |
| Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2 | Phase 2 / Phase 3 | Completed | University Hospital, Bordeaux | 412 | 2020-07-29 | 2026-05-12 |
| To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan - Primary Hypercholesterolemia, Hypertension | Phase 3 | Unknown | Hanlim Pharm. Co., Ltd. | 156 | 2020-07-15 | 2020-12-09 |
| Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 Hydroxychloroquine, Azithromycin, Telmisartan - COVID-19 Infection | Phase 3 | Terminated | University Hospital, Strasbourg, France | 16 | 2020-04-25 | 2022-07-11 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg, Placebo oral capsule - Cognitive Decline, Intracerebral Hemorrhage | Phase 3 | Terminated | The George Institute | 1 | 2020-02-27 | 2021-04-01 |
| Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine Ezetimibe/Rosuvastatin, Telmisartan, Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET - Hypercholesterolemia, Hypertension | Phase 3 | Completed | Addpharma Inc. | 131 | 2020-01-23 | 2021-05-12 |
| Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan Ezetimibe/Rosuvastatin, Telmisartan - Hypercholesterolemia, Hypertension | Phase 3 | Completed | Addpharma Inc. | 180 | 2019-02-26 | 2021-01-15 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Placebo - Intracerebral Haemorrhage (ICH), Hypertension | Phase 3 | Completed | The George Institute | 1671 | 2017-09-28 | 2025-09-12 |
| Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia Telmisartan + Amlodipine + Rosuvastatin, Telmisartan + Amlodipine, Telmisartan + Rosuvastatin - Hypertension, Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 129 | 2016-10-07 | 2018-02-01 |
| Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg), Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo), Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg) - Dyslipidemia With Hypertension | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 126 | 2016-09-20 | 2018-07-06 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic) | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2026-11-04 |
| Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg - Hypertension | Phase 3 | Completed | Yuhan Corporation | 381 | 2015-12-01 | 2024-11-12 |
| Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia Telmisartan/Amlodipine, Rosuvastatin, Telmisartan - Hypertension With Hyperlipidemia | Phase 3 | Completed | IlDong Pharmaceutical Co Ltd | 134 | 2015-11-24 | 2018-06-25 |
Showing 20 of 61. Sign in to see all of them.
Hypertension (45) · COVID-19 (5) · Diabetes Mellitus, Type 2 (3) · Metabolic Syndrome (3) · Cerebral Hemorrhage (2) · Coronavirus Infections (2) · Disease (2) · Dyslipidemias (2) · Essential Hypertension (2) · Familial paroxysmal dystonia (2) · Heart Diseases (2) · Hypercholesterolemia (2) · Hyperlipidemias (2) · Polycystic Kidney Diseases (2) · Polycystic Kidney, Autosomal Dominant (2)
Boehringer Ingelheim (27) · IlDong Pharmaceutical Co Ltd (3) · ANRS, Emerging Infectious Diseases (2) · Addpharma Inc. (2) · George Medicines PTY Limited (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · The George Institute (2) · Yuhan Corporation (2) · Chong Kun Dang Pharmaceutical (1) · Daewon Pharmaceutical Co., Ltd. (1) · EMS (1) · Hamilton Health Sciences Corporation (1) · Hanlim Pharm. Co., Ltd. (1) · Heidelberg University (1) · Jeil Pharmaceutical Co., Ltd. (1)
South Korea (16) · France (9) · United States (8) · Japan (7) · Netherlands (7) · Canada (6) · Germany (6) · United Kingdom (6) · Australia (5) · Czechia (5) · Sweden (5) · Taiwan (5) · Finland (4) · Italy (4) · South Africa (4)
Anthony Rodgers, Professor (2) · Arlene Chapman, M.D. (2) · Hyo Soo Kim, M.D., Ph.D (2) · Marva Moxey-Mims, M.D. (2) · Robert Schrier, M.D. (2) · Ronald Perrone, M.D. (2) · Vicente Torres, M.D. (2) · Arya M Sharma, MD, FRCPC (1) · Charity G Moore, MS,PhD (1) · Charity G Moore, PhD (1) · Colin McArthur, Dr (1) · Craig Anderson (1)
PMID 34473343, PMID 39356039, PMID 14630977, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 19191674, PMID 22090469, PMID 22205355, PMID 23731019, PMID 23810874, PMID 24653513, PMID 25111236, PMID 25399731, PMID 25399733, PMID 29248384, PMID 29673890, PMID 30665829, PMID 30803434, PMID 30904178, PMID 32267771, PMID 32876697, PMID 33050924, PMID 33394942, PMID 33509275, PMID 33631065, PMID 34022170, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34606578, PMID 34994269, PMID 35315874, PMID 36525245, PMID 36574985, PMID 36918388, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37119829, PMID 37250503, PMID 37256341, PMID 37489818, PMID 37877585, PMID 37888913, PMID 38454482, PMID 38682786, PMID 39217570
2008 (2), U01DK062401 (2), U01DK082230 (2), 2015 (1), 2023 (1)